Core Viewpoint - Enwei Pharmaceutical has announced its investment in a partnership focused on early and growth-stage companies, particularly in the medical and technology sectors [1] Investment Details - Enwei Pharmaceutical will invest 20 million yuan, accounting for 9.95% of the partnership [1] - The partnership will primarily invest in innovative drugs, medical devices, enterprise-level services, and hard technology [1]

Core Viewpoint - Enwei Pharmaceutical (301331.SZ) announced its participation as a limited partner in establishing the Jiaxing Panlin Jiayi Venture Capital Partnership (Limited Partnership) with a capital commitment of 20 million yuan [1] Investment Details - The total scale of the fund is 201 million yuan, focusing on investments in healthcare (innovative drugs, innovative medical devices) and technology (enterprise-level services, hard technology) [1] - The partnership still needs to complete the registration with the Asset Management Association of China and the business change registration, indicating uncertainty in the implementation process [1] Investment Risks - The company’s investment may face a longer investment return period, as well as risks related to the inability of investment projects to achieve expected returns or potential investment failures [1]

Core Viewpoint - Enwei Pharmaceutical (301331.SZ) has signed a partnership agreement to invest in a venture capital fund focusing on early and growth-stage companies in the healthcare and technology sectors [1] Group 1: Investment Details - The company will act as a limited partner, contributing RMB 20 million to the investment fund, which represents a 9.9502% stake [1] - The partnership includes Shanghai Panlin Hongyu Enterprise Management Partnership (Limited Partnership), Tangshan Jinkun Chemical Co., Ltd., and Li Jiao Jiao [1] Group 2: Investment Focus - The venture capital fund will primarily invest in early and growth-stage enterprises [1] - Investment directions include healthcare (innovative drugs, innovative medical devices) and technology (enterprise-level services, hard technology) [1]

证券代码：301331 证券简称：恩威医药 公告编号：2025-052 恩威医药股份有限公司 关于与专业投资机构共同投资设立基金的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1、投资标的名称：嘉兴磐霖嘉颐创业投资合伙企业（有限合伙）（以下简称"投资 基金"、"基金"或"合伙企业"）。 2、投资金额：恩威医药股份有限公司（以下简称"公司"）作为有限合伙人以自有 资金认缴出资人民币 2,000 万元。 3、相关风险提示：合伙企业尚需完成中国证券投资基金业协会备案和工商变更登 记手续，实施过程存在不确定性。因合伙企业投资周期较长、流动性较低，公司本次投 资可能面临较长的投资回报期。在运营过程中合伙企业将受宏观经济、行业周期、市场 变化、投资标的经营情况等多种因素影响，可能存在投资项目不能实现预期收益或投资 失败的风险。敬请投资者注意投资风险。 一、对外投资概述 近日，公司与上海磐霖鸿裕企业管理合伙企业（有限合伙）（以下简称"磐霖鸿裕"）、 唐山金坤化工有限公司、李姣姣等共同签署了《嘉兴磐霖嘉颐创业投资合伙企业（有限 合伙）合伙协议》（以下简 ...

Core Viewpoint - The A-share market is seeing active trading in flu-related stocks, driven by an early peak in respiratory syncytial virus (RSV) and flu activity in China, as reported by the National Disease Control [1][2]. Group 1: Market Activity - Aipeng Medical has risen over 10%, while Panlong Pharmaceutical has reached a 10% limit up, with other companies like Rejing Bio and Dongfang Bio also seeing significant gains [1]. - The latest flu monitoring report indicates an increase in flu activity in southern provinces and a rise in northern provinces during the 44th week of 2025 [1]. Group 2: Key Data on Stocks - Aipeng Medical (300753) has a market cap of 3.969 billion and a year-to-date increase of 79.09% [2]. - Panlong Pharmaceutical (002864) has a market cap of 3.788 billion and a year-to-date increase of 18.84% [2]. - Rejing Bio (688068) has a market cap of 14 billion and a year-to-date increase of 144.44% [2]. - Dongfang Bio (688298) has a market cap of 5.836 billion with a slight year-to-date decrease of 1.30% [2]. - Other notable stocks include Te Yi Pharmaceutical (002728) with a market cap of 6.961 billion and a year-to-date increase of 52.45% [2].

Core Viewpoint - Enwei Pharmaceutical, established in 2005 and listed in 2022, specializes in the pharmaceutical sector with a focus on gynecology, pediatrics, and respiratory medications, holding a notable brand presence in China [1] Financial Performance - For Q3 2025, Enwei Pharmaceutical reported revenue of 637 million yuan, ranking 51st among 69 companies in the industry, with the industry leader, Baiyunshan, generating 61.606 billion yuan [2] - The company's net profit for the same period was 36.5847 million yuan, placing it 46th in the industry, while the top performer, Yunnan Baiyao, reported a net profit of 4.789 billion yuan [2] Financial Ratios - As of Q3 2025, Enwei Pharmaceutical's debt-to-asset ratio was 27.60%, lower than the industry average of 32.81% [3] - The company's gross profit margin stood at 48.22%, which is below the industry average of 52.44% [3] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 13.72% to 6,340, while the average number of shares held per shareholder increased by 261.71% to 16,200 [5]

Core Viewpoint - Enwei Pharmaceutical reported a revenue of 188 million yuan for Q3 2025, representing an increase of 8.97% year-on-year, but incurred a net loss of 1.76 million yuan due to production line upgrades and increased marketing expenses [1] Group 1 - The company achieved a revenue of 188 million yuan in Q3 2025, which is an 8.97% increase compared to the same period last year [1] - The net profit for the quarter was a loss of 1.76 million yuan, primarily due to the impact of technical upgrades on the core product production line and rapid expansion of the e-commerce division [1] - The production line upgrade for the core product, Jieryin Wash, affected the shipment progress of certain product specifications, but the construction was nearly completed by the end of Q3, allowing for recovery in production and shipping [1]

Core Viewpoint - The company has announced the achievement of conditions for the second phase of its restricted stock incentive plan, allowing 106 eligible participants to claim a total of 799,271 shares at an adjusted price of 13.48 yuan per share, which represents 0.7768% of the company's total share capital [10][40]. Financial Data - The company confirmed that the third-quarter financial report was not audited [7]. - The financial report includes no adjustments or restatements of previous years' accounting data [3]. - The company reported no non-recurring gains or losses applicable [3]. Shareholder Information - The total number of shareholders holding more than 5% of shares and the top ten shareholders' holdings were not applicable for this report [5]. - The company has not experienced any changes in the lending of shares by major shareholders due to margin trading [5]. Incentive Plan Details - The second phase of the restricted stock incentive plan involves 106 eligible participants and a total of 799,271 shares [9][10]. - The adjusted grant price for the second phase is set at 13.48 yuan per share [11]. - The source of the shares for this incentive plan is from the company's repurchase of A-share common stock from the secondary market [12]. Approval Process - The board of directors approved the achievement of the second phase conditions on October 29, 2025, with unanimous support [36]. - The incentive plan has undergone necessary approvals and has been publicly disclosed as required [47][50]. Performance Conditions - The performance assessment for the incentive plan is based on company-level metrics for the fiscal years 2023-2025, with specific targets set for each year [22]. - Individual performance assessments will also be conducted according to the company's existing compensation and evaluation regulations [22]. Impact on Financial Status - The company anticipates that the stock grants will not significantly impact its financial status or operational results, as the total share capital will remain unchanged [49]. - The company will adjust the accounting treatment of the stock grants according to the applicable accounting standards [49].

Core Viewpoint - The company has adjusted the grant price and quantity of the second category of restricted stock in its 2023 incentive plan, which will not significantly impact its financial status or operational results [4][15][27]. Summary by Sections Incentive Plan Adjustments - The company held its third board meeting on October 29, 2025, where it approved the adjustment of the grant price for the second category of restricted stock to 13.48 yuan per share and agreed to void 21.8821 thousand shares that were granted but not vested [9][25]. - The adjustment was made following the completion of the 2024 annual profit distribution, which involved a cash dividend of 1.80 yuan per 10 shares, totaling approximately 18.19 million yuan [10][15]. Approval Process - The company followed necessary approval procedures for the 2023 restricted stock incentive plan, including meetings of the board and supervisory committee, and received independent opinions from legal and financial advisors [2][4][21]. - The plan was publicly disclosed, and no objections were raised during the internal announcement period [6][22]. Impact of Adjustments - The adjustments to the grant price and the voiding of certain shares will not materially affect the company's financial condition or management stability, and the management team will continue to fulfill its responsibilities [15][27]. - The voided shares accounted for approximately 0.2127% of the company's total share capital [26]. Legal Opinions - Legal opinions confirm that the adjustments and the conditions for vesting have been met in accordance with relevant regulations, ensuring compliance with the management and incentive plan guidelines [17][29].

证券代码：301331 证券简称：恩威医药 公告编号：2025-046 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 恩威医药股份有限公司（以下简称"公司"）第三届董事会第八次会议于 2025 年 10 月 29 日以现场及通讯方式召开。本次会议通知于 2025 年 10 月 20 日以通 讯方式发出，本次会议应参会董事 8 名，实际参会董事 8 名，黎春独立董事以 通讯方式参加会议。会议由董事长薛永江主持召开。本次会议的召开符合《公 司法》和《公司章程》的有关规定，所做决议合法有效。 二、董事会会议审议情况 1、审议通过了《关于<公司 2025 年第三季度报告>的议案》 经审核，董事会认为：公司 2025 年第三季度报告包含的信息公允、全面、 真实的反映了本报告期的财务状况和经营成果等事项，所披露的信息真实、准 确、完整，不存在任何虚假记载、误导性陈述或重大遗漏。 恩威医药股份有限公司 第三届董事会第八次会议决议公告 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）上的相关 公告。 表决结果：8 票同意，0 ...